A Teeple1, L A Ellis1, L Huff2, C Reynolds2, S Ginsburg3, L Howard4, D Walls5, J R Curtis6. 1. a Janssen Scientific Affairs, LLC , Horsham , PA , USA. 2. b Benfield, a Division of Gallagher Benefit Services, Inc. , Webster Groves , MO , USA. 3. c Global Healthy Living Foundation , Upper Nyack , NY , USA. 4. d National Psoriasis Foundation , Alexandria , VA , USA. 5. e BDJ Solutions, LLC , Melrose , MA , USA. 6. f University of Alabama at Birmingham , Birmingham , AL , USA.
Abstract
OBJECTIVE: This study was designed to understand the level of familiarity of US rheumatologists, gastroenterologists and dermatologists with biosimilar therapies, their experience with non-medical switching (switching medications for reasons unrelated to patient health) of patients between biologics and their attitudes towards switching from a biologic to a biosimilar. METHODS: A total of 297 US physicians who currently prescribe biologics for their patients completed a 15-minute online survey. Rheumatologists, dermatologists and gastroenterologists were included. RESULTS: The majority of physicians (84%) did not want stable patients undergoing a non-medical switch to a biosimilar. While 60% of physicians believed non-medical switching to biosimilars may have a positive impact on healthcare system costs, multiple negative impacts were also expected. A majority of physicians anticipated a negative impact on patient mental health (59%), treatment efficacy (57%), patient safety (53%) and physician office management (60%). CONCLUSIONS: The majority of physicians had concerns regarding non-medical switching to biosimilars and the impact such switching would have on patient care and physician practice.
OBJECTIVE: This study was designed to understand the level of familiarity of US rheumatologists, gastroenterologists and dermatologists with biosimilar therapies, their experience with non-medical switching (switching medications for reasons unrelated to patient health) of patients between biologics and their attitudes towards switching from a biologic to a biosimilar. METHODS: A total of 297 US physicians who currently prescribe biologics for their patients completed a 15-minute online survey. Rheumatologists, dermatologists and gastroenterologists were included. RESULTS: The majority of physicians (84%) did not want stable patients undergoing a non-medical switch to a biosimilar. While 60% of physicians believed non-medical switching to biosimilars may have a positive impact on healthcare system costs, multiple negative impacts were also expected. A majority of physicians anticipated a negative impact on patient mental health (59%), treatment efficacy (57%), patient safety (53%) and physician office management (60%). CONCLUSIONS: The majority of physicians had concerns regarding non-medical switching to biosimilars and the impact such switching would have on patient care and physician practice.
Authors: Marianna Olave; Criswell Lavery; Charles E Leonard; Vincent Lo Re; Judy A Shea; Jonathan Kay; Joshua F Baker Journal: Drugs Ther Perspect Date: 2021-06-08
Authors: Louise C Druedahl; Sofia Kälvemark Sporrong; Timo Minssen; Hans Hoogland; Marie Louise De Bruin; Marco van de Weert; Anna Birna Almarsdóttir Journal: PLoS One Date: 2022-01-11 Impact factor: 3.240